Literature DB >> 2153184

Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults.

P C Johnson1, J J Mathewson, H L DuPont, H B Greenberg.   

Abstract

In a multiple-challenge study of US adult volunteers with low or high levels of serum antibody to Norwalk virus, Norwalk inoculum 8FIIa was administered to 42 subjects, 22 were challenged 6 months later, and 19 received a third challenge after 6 more months. All 12 with high (greater than or equal to 1:200) but only 19 of 30 with low (less than 1:100) prechallenge titers experienced illness or a fourfold increase in titer after the first challenge (P less than .025). Only 4 of those challenged twice became ill; all had low initial titers but 3 had high titers before the second challenge. None became ill after a third challenge. Nine (47%) had high titers immediately before the third challenge; 3 had low titers before and after each challenge and remained asymptomatic. Thus, preexisting serum antibody to Norwalk virus does not seem to be associated with protective immunity, but antibody levels become associated with protection after repetitive exposure. Short-term resistance lasts greater than or equal to 6 months after challenge, and a small percentage of resistant individuals maintain low antibody titers even after multiple challenges.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153184     DOI: 10.1093/infdis/161.1.18

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  89 in total

1.  Foodborne viral infections.

Authors:  A Hale
Journal:  BMJ       Date:  1999-05-29

2.  A Secreted Viral Nonstructural Protein Determines Intestinal Norovirus Pathogenesis.

Authors:  Sanghyun Lee; Hejun Liu; Craig B Wilen; Zoi E Sychev; Chandni Desai; Barry L Hykes; Robert C Orchard; Broc T McCune; Ki-Wook Kim; Timothy J Nice; Scott A Handley; Megan T Baldridge; Gaya K Amarasinghe; Herbert W Virgin
Journal:  Cell Host Microbe       Date:  2019-05-23       Impact factor: 21.023

Review 3.  Burden of norovirus in healthcare facilities and strategies for outbreak control.

Authors:  A Kambhampati; M Koopmans; B A Lopman
Journal:  J Hosp Infect       Date:  2015-02-04       Impact factor: 3.926

4.  Murine norovirus 1 infection is associated with histopathological changes in immunocompetent hosts, but clinical disease is prevented by STAT1-dependent interferon responses.

Authors:  Shannon M Mumphrey; Harish Changotra; Tara N Moore; Ellen R Heimann-Nichols; Christiane E Wobus; Michael J Reilly; Mana Moghadamfalahi; Deepti Shukla; Stephanie M Karst
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

5.  Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.

Authors:  Maria Malm; Kirsi Tamminen; Suvi Lappalainen; Hanni Uusi-Kerttula; Timo Vesikari; Vesna Blazevic
Journal:  Clin Vaccine Immunol       Date:  2015-04-22

6.  Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.

Authors:  Patrick R Harrington; Boyd Yount; Robert E Johnston; Nancy Davis; Christine Moe; Ralph S Baric
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors:  Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

Review 8.  Chronic norovirus infection and common variable immunodeficiency.

Authors:  J Woodward; E Gkrania-Klotsas; D Kumararatne
Journal:  Clin Exp Immunol       Date:  2016-11-16       Impact factor: 4.330

Review 9.  Developments in understanding acquired immunity and innate susceptibility to norovirus and rotavirus gastroenteritis in children.

Authors:  Daniel C Payne; Umesh D Parashar; Benjamin A Lopman
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

10.  Type I and type II interferons inhibit the translation of murine norovirus proteins.

Authors:  Harish Changotra; Yali Jia; Tara N Moore; Guangliang Liu; Shannon M Kahan; Stanislav V Sosnovtsev; Stephanie M Karst
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.